An interventional study of Picankibart in Palmoplantar Pustulosis, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.
Among the 206 studies in Psoriasis with a site in China, this one is the 135th largest by planned enrollment of the 182 interventional ones that give a count, is one of 18 that started in 2026, is one of 20 with no phase, reaches primary completion later than 53 of the 65 other live ones, and was the 192nd registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18+
Zhejiang Wenda Pharma Technology LTD. · Sites in China
Ages 18–75 · Healthy volunteers
First Hospital of China Medical University · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 55 · Phase 3 60 · Phase 4 12
First in 2005; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 171 across the 182 interventional studies, 191 across the 24 observational. Of the 111 that completed or were terminated, 16 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 206 have an industry lead sponsor. The 10 most frequent:
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
Xijing Hospital has 9 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
20 of the studies in Psoriasis with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07672561Phase 3Zhejiang Wenda Pharma Technology LTD.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis | 2026-11-30 |
| NCT07543224Phase 3Reistone Biopharma Company LimitedA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis. | 2027-01 |
| NCT07326813Phase 3InventisBio Co., LtdA Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis | 2027-07-12 |
| NCT07130604Phase 3InventisBio Co., LtdEvaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis | 2027-07-28 |
| NCT07724366Phase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | 2027-09 |
Add all 20 to your calendar (.ics) → With an account.
Among the 206 studies in Psoriasis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Inclusion Criteria
Exclusion Criteria
Withdrawal Criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Failed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions.
Considered suitable for treatment with picankibart as assessed by the clinician.
Voluntarily participate in the study and provide written .
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Picankibart
Induction phase: Picankibart 200 mg administered subcutaneously at Weeks 0, 4, and 8. Maintenance phase: Picankibart 100 mg administered subcutaneously at Weeks 20, 32, and 44.
Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)
Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)
Time frame: 16 Week
Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)
Time frame: 16 Week
Plan to share: Yes
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Oct 2027, 18 months later.
Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 18 months is below that.
Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Picankibart